Abstract
Telomeres are specialized structures at the end of human chromosomes. Telomere length decreases with eachcell division, thus, reflecting the mitotic history of somatic cells. Telomerase, the ribonucleoprotein enzyme which main-tains telomeres of eukaryotic chromosomes, is up-regulated in the vast majority of human neoplasia but not in normal so-matic tissues. In contrast to other somatic cells, normal primitive human hematopoietic cells and some peripheral bloodcells expressed low levels of telomerase activity. This activity is thought to play an important role in self-renewal of he-matopoietic stem cells. In malignant disorders, telomere lengths are generally shortened and telomerase expression andactivity enhanced with high differences in the levels. Although it is necessary to be cautious in interpreting these data,there are indications that telomere length and telomerase expression and activity can serve as a molecular marker of theclinical progression and prognosis of most leukemias. Approaches that directly target telomerase, telomeres or telomeraseregulatory mechanisms have been developed. Some of these anti-telomerase strategies in combination with conventionaldrugs proved to be promising in some types of leukemias.
Keywords: Telomerase, telomere, leukemia, anti-telomerase strategies
Current Pharmaceutical Biotechnology
Title: Diagnostics, Prognostic and Therapeutic Exploitation of Telomeres and Telomerase in Leukemias
Volume: 7 Issue: 3
Author(s): Laure Deville, Josette Hillion, Michel Lanotte, Philippe Rousselot and Evelyne Segal-Bendirdjian
Affiliation:
Keywords: Telomerase, telomere, leukemia, anti-telomerase strategies
Abstract: Telomeres are specialized structures at the end of human chromosomes. Telomere length decreases with eachcell division, thus, reflecting the mitotic history of somatic cells. Telomerase, the ribonucleoprotein enzyme which main-tains telomeres of eukaryotic chromosomes, is up-regulated in the vast majority of human neoplasia but not in normal so-matic tissues. In contrast to other somatic cells, normal primitive human hematopoietic cells and some peripheral bloodcells expressed low levels of telomerase activity. This activity is thought to play an important role in self-renewal of he-matopoietic stem cells. In malignant disorders, telomere lengths are generally shortened and telomerase expression andactivity enhanced with high differences in the levels. Although it is necessary to be cautious in interpreting these data,there are indications that telomere length and telomerase expression and activity can serve as a molecular marker of theclinical progression and prognosis of most leukemias. Approaches that directly target telomerase, telomeres or telomeraseregulatory mechanisms have been developed. Some of these anti-telomerase strategies in combination with conventionaldrugs proved to be promising in some types of leukemias.
Export Options
About this article
Cite this article as:
Deville Laure, Hillion Josette, Lanotte Michel, Rousselot Philippe and Segal-Bendirdjian Evelyne, Diagnostics, Prognostic and Therapeutic Exploitation of Telomeres and Telomerase in Leukemias, Current Pharmaceutical Biotechnology 2006; 7 (3) . https://dx.doi.org/10.2174/138920106777549768
DOI https://dx.doi.org/10.2174/138920106777549768 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effects of Cantharidin and Cantharidin Derivates on Tumour Cells
Anti-Cancer Agents in Medicinal Chemistry Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets Biologically Active Peptides Interacting with the G Protein-Coupled Formylpeptide Receptors
Protein & Peptide Letters Target Genetic Abnormalities for the Treatment of Colon Cancer and Its Progression to Metastasis
Current Drug Targets DNA Methylation as a Target of Epigenetic Therapeutics in Cancer
Anti-Cancer Agents in Medicinal Chemistry Status of Flavonols as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Current Cancer Therapy Reviews A Direct Interaction Between Mitochondrial Proteins and Amyloid-β Peptide and its Significance for the Progression and Treatment of Alzheimer’s Disease
Current Medicinal Chemistry Alzheimer’s Disease and Antioxidant Therapy: How Long How Far?
Current Medicinal Chemistry Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Turning Tumor-Promoting Copper into an Anti-Cancer Weapon via High-Throughput Chemistry
Current Medicinal Chemistry HDACs and HDAC Inhibitors in Urothelial Carcinoma – Perspectives for an Antineoplastic Treatment
Current Medicinal Chemistry LRP/LR as an Alternative Promising Target in Therapy of Prion Diseases, Alzheimers Disease and Cancer
Infectious Disorders - Drug Targets Plant Glycosides and Aglycones Displaying Antiproliferative and Antitumour Activities – A Review
Current Bioactive Compounds An Overview of Labeled Porphyrin Molecules in Medical Imaging
Recent Patents and Topics on Imaging (Discontinued) Killing the Messenger: Antisense DNA and siRNA
Current Drug Targets Management of Glioblastoma Multiforme by Phytochemicals: Applications of Nanoparticle-Based Targeted Drug Delivery System
Current Drug Targets Antitubulinic effect of New Fluorazone Derivatives on Melanoma Cells
Anti-Cancer Agents in Medicinal Chemistry Novel Multifunctional Anti-Alzheimer Drugs with Various CNS Neurotransmitter Targets and Neuroprotective Moieties
Current Alzheimer Research Eremurus spectabilis, Rich Source of Isoorientin: Isolation, Quantification and Anti-Cancer Activity on SH-SY5Y Neuroblastoma Cells
Current Pharmaceutical Analysis Membrane Targeted Chemotherapy with Hybrid Liposomes for Tumor Cells Leading to Apoptosis
Current Pharmaceutical Design